The role of IL-17 in the treatment of psoriatic arthritis

References

• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis. 2005;64(2):14–17.
   Google Scholar
• Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014;28(5):663–672.
   PubMed Web of Science ®Google Scholar
• Coates LC, Anderson RR, Fitzgerald O, et al. Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. J Rheumatol. 2008;35(7):1438–1442.
   PubMed Web of Science ®Google Scholar
• Fénix-Caballero S, Alegre-Del Rey EJ, Castaño-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther. 2013;38(4):286–293.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intollerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49(6):1107–1111.
   PubMed Web of Science ®Google Scholar
• Reddy SM, Crean S, Martin AL, et al. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol. 2016;35(12):2955–2966.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs. 2016;76(6):663–673.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Parsons WJ, Perrotta FM. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2016;43(5):918–923.
   PubMed Web of Science ®Google Scholar
• Perrotta FM, Marchesoni A, Minimal Disease LE. Activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol. 2016;43(2):350–355.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford). 2013;52(10):1914–1919.
   PubMed Web of Science ®Google Scholar
• Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–1248.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Dobrowolska A, Rychlewska-Hańczewska A, et al. New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis. Autoimmunity. 2016;49(7):435–450.
   PubMed Web of Science ®Google Scholar
• Marinoni B, Ceribelli A, Massarotti MS, et al. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9–19.
   PubMedGoogle Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155–174.
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181:2799–2805.
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435–440.
   PubMed Web of Science ®Google Scholar
• Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467–476.
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–68.
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–898.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discovery. 2012;11:763–776.
   PubMed Web of Science ®Google Scholar
• Smith JA, Colbert RA. Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: th17 and beyond. Arthritis Rheumatol (Hoboken, NJ). 2014;66:231–241.*.
   Web of Science ®Google Scholar
• Mc Ardle A, Flatley B, Pennington SR, et al. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. 2015;17:141.
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–130.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001;167:1004–1013.
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307–2317.
   PubMed Web of Science ®Google Scholar
• Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272–1281.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092–1102.
   PubMed Web of Science ®Google Scholar
• Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449–1453.
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41:199–204.
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Suzuki E, Chao CC, et al. IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1284–1292.
   PubMed Web of Science ®Google Scholar
• Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39(6):696–707.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. PSUMMIT I Study Group. Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: results from the PSUMMIT 1 trial. Arthritis Care Res (Hoboken). 2015;67(12):1739–1749.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for Ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2016. [Epub ahead of print]. DOI:10.1016/j.jaad.2016.11.042
   Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2016. [Epub ahead of print]. DOI:10.1016/j.jaad.2016.11.041
   Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WB et al. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study. Poster session presented at ACR/ARHP Annual Meeting; 2016; Washington, DC.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis–results of two phase trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. FUTURE 1 Study Group. secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Gossec L, et al. FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017;76(1):203–207.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–4630.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713–1717.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1914–1921.
   PubMed Web of Science ®Google Scholar
• Coates LC, Mease P, Kirkham P, et al. Secukinumab improves minimal disease activity response rates in patients with active psoriatic arthritis: data from the randomized phase 3 study, Future 2. Ann Rheum Dis. 2016;75:605.
   Web of Science ®Google Scholar
• van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2016. [Epub ahead of print]. DOI:10.1111/jdv.13990
   Web of Science ®Google Scholar
• Mease PJ, Van Der Heijde D, Ritchlin CT, et al. SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Wasilewska A, Winiarska M, Olszewska M, et al. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33(4):247–252.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. An anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Glatt S, Strimenopoulou F, Shaw S, et al. Bimekizumab, a monoclonal antibody that inhibits both IL-17A and IL-17F, produces a profound response in both skin and joints: results of an early-phase, proof-of-concept study in psoriatic arthritis. Ann Rheum Dis. 2016;75((suppl):2.
   Google Scholar
• Ruzek M, Conlon D, Mansikka H, et al. a novel dual variable domain (DVD)-Ig™, targeting TNF and IL-17, inhibits peripheral blood mononuclear cell production of GM-CSF and decreases lymphocyte expression of CXCR4 in healthy subjects. Ann Rheum Dis. 2015;74:487.
   Google Scholar
• Mease P, Genovese M, Weinblatt M, et al. Safety and efficacy of ABT-122, a TNF and IL-17–targeted Dual Variable Domain (DVD)–Ig™, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial. Poster session presented at ACR/ARHP Annual Meeting; 2016; Washington, DC.
   Google Scholar